Premium
Safety aspects and pharmacokinetics of inhaled aerosolized gadolinium
Author(s) -
Berthezëne Yves,
Mühler Andreas,
Lang Philipp,
Shames David M.,
Clëment Olivier,
Rosenau Werner,
Kuwatsuru Ryohei,
Brasch Robert C.
Publication year - 1993
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.1880030121
Subject(s) - inhalation , medicine , pharmacokinetics , aerosolization , lung , toxicity , hemodynamics , anesthesia , pharmacology
This study evaluated the pharmacokinetics and potential toxicity of inhaled aerosolized gadopen‐tetate dimeglumine. The pharmacokinetics were evaluated with in vitro relaxometry of the lungs, blood, urine, and liver before and for up to 36 hours after a 5‐minute inhalation of aerosolized gadopen‐tetate dimeglumine (0.25 mol/L). For assessment of potential toxicity, hemodynamic variables were monitored during and for 10 minutes after inhalation. Extravascular lung water was measured before and after exposure. Finally, the potential for tissue damage was evaluated histologically. Pulmonary clearance of aerosolized gadopentetate dimeglumine was monoexponential with a half‐time of 2.16 hours. Aerosolized gadopentetate dimeglumine was excreted through the kidneys, as shown by the decrease in urinary T1. Renal elimination was completed by 30 hours. No acute hemodynamic effect, histologic change, or induction of edema was demonstrated. This study shows that inhalation of aerosolized gadopentetate dimeglumine is well tolerated in rats and favors the further evaluation of this administration route, including clinical trials.